FI971750A - Kompositioner och behandling för multipel sclerosis - Google Patents

Kompositioner och behandling för multipel sclerosis Download PDF

Info

Publication number
FI971750A
FI971750A FI971750A FI971750A FI971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A
Authority
FI
Finland
Prior art keywords
compositions
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
FI971750A
Other languages
English (en)
Finnish (fi)
Other versions
FI971750A0 (sv
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of FI971750A0 publication Critical patent/FI971750A0/sv
Publication of FI971750A publication Critical patent/FI971750A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI971750A 1994-10-25 1997-04-24 Kompositioner och behandling för multipel sclerosis FI971750A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
FI971750A0 FI971750A0 (sv) 1997-04-24
FI971750A true FI971750A (sv) 1997-06-24

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971750A FI971750A (sv) 1994-10-25 1997-04-24 Kompositioner och behandling för multipel sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (sv)
JP (1) JPH10504039A (sv)
AU (1) AU4278296A (sv)
BR (1) BR9509438A (sv)
CA (1) CA2203629A1 (sv)
CZ (1) CZ122697A3 (sv)
FI (1) FI971750A (sv)
HU (1) HUT77047A (sv)
IL (1) IL115766A0 (sv)
IS (1) IS4466A (sv)
NO (1) NO971900L (sv)
PL (1) PL324091A1 (sv)
SI (1) SI9520118A (sv)
SK (1) SK51297A3 (sv)
WO (1) WO1996012737A2 (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
ATE296444T1 (de) 1996-03-21 2005-06-15 Circassia Ltd Kryptische peptide und verfahren zu ihrer identifizierung
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
AU3789099A (en) * 1998-05-05 1999-11-23 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (ja) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド 細胞、神経系−特異的抗原およびそれらの用途
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
ATE431410T1 (de) 2002-03-27 2009-05-15 Aegera Therapeutics Inc Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP2572734B1 (en) 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
AU2010234743A1 (en) 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CN102781465A (zh) 2009-10-12 2012-11-14 生命生物实验室有限公司 用于治疗多发性硬化的组合物
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
CN106102835B (zh) 2014-01-13 2020-11-03 博格有限责任公司 烯醇酶1(eno1)组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU642693B2 (en) * 1989-12-20 1993-10-28 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
BR9106114A (pt) * 1990-03-02 1993-03-09 Autoimmune Inc Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
JP3712260B2 (ja) * 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
EP0863155B1 (en) * 1992-04-09 2002-01-23 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
CA2172512A1 (en) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
EP0752879A4 (en) * 1994-04-08 1999-07-21 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES WITH TOLERANCE INDUCING AGENTS AND / OR ORAL TH2-ENHANCING CYTOKINES
SI9520059A (en) * 1994-05-10 1997-08-31 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis.
JP3558347B2 (ja) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2205532A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
BR9509438A (pt) 1997-12-23
WO1996012737A2 (en) 1996-05-02
IS4466A (is) 1997-04-17
NO971900D0 (no) 1997-04-24
PL324091A1 (en) 1998-05-11
IL115766A0 (en) 1996-01-19
AU4278296A (en) 1996-05-15
SI9520118A (sl) 1998-08-31
CA2203629A1 (en) 1996-05-02
JPH10504039A (ja) 1998-04-14
NO971900L (no) 1997-06-25
FI971750A0 (sv) 1997-04-24
EP0787147A1 (en) 1997-08-06
CZ122697A3 (en) 1997-09-17
SK51297A3 (en) 1998-03-04
HUT77047A (hu) 1998-03-02
WO1996012737A3 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
FI971750A (sv) Kompositioner och behandling för multipel sclerosis
FI971969A (sv) Kompositioner för behandling av hemorrojder och användningsmetod
FI970563A0 (sv) Förbättrad rengöringskomposition
FI955980A (sv) Förfarande och anordning för omordning
DE69513916T2 (de) Oberflächenbehandlungszusammensetzung
FI964330A (sv) Förfarande och anordning för trapphissar
DE69521804D1 (de) Reinigungszusammensetzungen
FI960483A (sv) Föränderlig sammansättning och förfaranden för användning av denna
FI962976A0 (sv) Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare
DE69527272D1 (de) Reinigungszusammensetzung
FI972306A (sv) Substituerade 2-arylkarbonyloximetyl-1,2,5-tiadiazolidin-3-oni-1,1-diozid-derivat och dessa innehållande kompositioner och förfaranden för deras användning
IL113661A0 (en) Compositions and treatment for multiple sclerosis
FI971138A0 (sv) Keramiska isolatorer och förfaranden för deras framställning
FI971376A0 (fi) Trofinin och trofininmedlande proteiner
DE69527268T2 (de) Reiningungszusammensetzung
FI91347C (sv) Förfarande för utförande av tidsintervallkoppling och tidskopplare
FI972307A (sv) 2-(2,3,5,6-tetrafluor-4-pyridyl)1,2,5-tiadiazolidin-3-oni-1,1-dioxider och dessa innehållande kompositioner och förfarande för deras användning
SE9400371L (sv) Kompositioner för inhalation
SE9403758D0 (sv) Arrangemang för rengöring
SE9402744D0 (sv) Komposition för permanentning av hår
SE9200329D0 (sv) Alldisk och allrengoeringsmedel
FIU940033U0 (fi) Braennbart uppvaermningsredskap foer bruk utomhus och i eldstaeder
SE9400370L (sv) Terapeutisk komposition för inhalation
ZA953730B (en) Compositions and treatment for multiple sclerosis
FI941614A0 (fi) Foerfarande och anordning foer saogning med bandsaog